16 / 25
Page 71
conferenceseries
.com
Volume 8
Journal of Biotechnology & Biomaterials
ISSN: 2155-952X
Pharma Biotech 2018
December 10-11, 2018
December 10-11, 2018 | Rome, Italy
23
rd
International Conference on
Pharmaceutical Biotechnology
Thyroid cancer incidence and clinicopathological differences in patients with end-stage renal failure
Mahir Kirnap, Aydıncan Akdur, Nazli Gülsoy Kirnap, Eda Yilmaz Akcay
and
Gokhan Moray
Baskent University, Turkey
Aim:
In the present, study we aimed to determine the prevalence of thyroid cancer and the clinicopathological properties of
papillary thyroid cancer (PTC) in a patient population undergoing dialysis for end-stage renal failure (ESRF).
Materials&Methods:
We retrospectively reviewedall thyroidultrasonography (USG) examinations performedbetween January
2007 and December 2015 to determine the incidence of nodular thyroid disease in ESRF and normal patient populations. For
both patient groups, differences between patient and tumor characteristics were evaluated in patients diagnosed to have PTC.
Results:
Among 29.381 patients, who underwent thyroid USG examination, 3.491 were included in the ESRF group (Group
1) and 25.890 in the control group (Group 2). Thyroid cancer was detected in 77 (2.2%) of 3.491 patients in Group 1 and 338
(1.3%) of 25.890 patients in Group 2. Thyroid cancer was significantly more prevalent in patients with ESRF (p<0.001).
Discussion:
When only patients with papillary thyroid cancer were considered, no significant difference existed between the
two groups with respect to the prevalence of PTC, although PTC cases in the ESRF group had a significantly higher rate of
aggressive characteristics such as capsule invasion, multifocality, and lymph node metastasis. Whereas thyroid cancer is more
common in patients with ESRF compared to normal controls, papillary thyroid cancer was not significantly more prevalent in
the ESRF group.
Conclusion:
PTC in the ESRF group having more aggressive properties than those in the control group suggests that PTC
should be diagnosed earlier in their course, treated more aggressively, and followed more closely in ESRF.
mahirkir@hotmail.comJ Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C8-110